Merck, Keytruda and colorectal cancer
Merck's Experimental Favezelimab/Keytruda Combo Fails In Late-Stage Colorectal Cancer Study
Merck & Co Inc (NYSE:MRK) released topline data from the KEYFORM-007 Phase 3 study of the fixed-dose combination of favezelimab and pembrolizumab versus the standard of care for pretreated patients with microsatellite-stable (MSS) metastatic colorectal cancer (mCRC).
Merck's Keytruda-LAG-3 combo fails to tame tough colorectal cancer in phase 3
An attempt by Merck & Co. to unlock the microsatellite stable (MSS) metastatic colorectal cancer market has ended in failure. | An attempt by Merck & Co. to unlock the microsatellite stable metastatic colorectal cancer market has ended in failure.
Research from the University of California, Irvine has revealed how disruption of the circadian clock, the body's internal, ...
Many people are simply unaware of the existence of the FIT test or underestimate its importance in colorectal cancer ...
A new study has identified two symptoms that occur in nearly half of all people diagnosed with early-onset colorectal cancer. Abdominal pain and blood in the stool were identified as symptoms ...
"Stool-based test offers a promising solution to reduce the burden of a colonoscopy," experts emphasized on September 21st, ...
Research from the University of California, Irvine has revealed how disruption of the circadian clock, the body's ...
Factors related to sex and gender can affect therapy outcomes and should not be overlooked in clinical practice or research.
Researchers sought to determine the effect of antibiotics on the risk of colorectal cancer recurrence after surgery.
Researchers also noticed that the mice used as models for Alzheimer’s disease who were given stool transplants from healthy ...
Symptoms of anaemia include fatigue, cold hands and feet, hair loss, brittle nails, cognitive issues like brain fog, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback